Diabetes kidney drug shows promise in slowing damage

NCT ID NCT03436693

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether canagliflozin, a diabetes drug, can slow kidney decline in 308 Japanese patients with diabetic nephropathy. Participants took either the drug or a placebo daily for about two years. The main goal was to see if fewer people on the drug had a 30% drop in kidney function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: canagliflozin
What this could lead to: If successful, this could provide a new option to slow kidney damage in people with diabetes-related kidney disease.
What could go wrong: This is a completed Phase 3 trial in Japanese patients only, so results may not apply to other populations. The drug may not significantly slow kidney decline compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetic kidney disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETIC NEPHROPATHY

Contacts and locations

Locations

Research site

Aichi, Japan
Research site

Chiba, Japan
Research site

Fukuoka, Japan
Research site

Fukushima, Japan
Research site

Gunma, Japan
Research site

Hiroshima, Japan
Research site

Hokkaido, Japan
Research site

Hyōgo, Japan
Research site

Ibaraki, Japan
Research site

Kagawa, Japan
Research site

Kagoshima, Japan
Research site

Kanagawa, Japan
Research site

Kumamoto, Japan
Research site

Mie, Japan
Research site

Nagano, Japan
Research site

Nagasaki, Japan
Research site

Okinawa, Japan
Research site

Osaka, Japan
Research site

Ōita, Japan
Research site

Saitama, Japan
Research site

Shizuoka, Japan
Research site

Tochigi, Japan
Research site

Tokyo, Japan
Research site

Wakayama, Japan
Research site

Yamagata, Japan
Research site

Yamaguchi, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.